MHRA approves GLP–1 receptor agonist Wegovy for new use

23 July 2024

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved a new indication for Wegovy (semaglutide) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.

The Danish diabetes and obesity giant Novo Nordisk’s (NOV: N) GLP-1 receptor agonist is already approved for use in the treatment of obesity and for weight management, to be used alongside diet, physical activity and behavioural support.

First quarter 2024 sales of Wegovy were 9.38 billion kroner ($1.37 billion), a 106% rise in the like 2023 period.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical